Comparative analysis of the combined therapeutic effects of bortezomib and lenalidomide

Bortezomib and lenalidomide are both important drugs in the treatment of multiple myeloma, but there are certain differences in their mechanisms of action and therapeutic effects. Bortezomib, as a proteasome inhibitor, can inhibit protein degradation pathways in tumor cells and induce cell apoptosis, thus exerting anti-tumor effects. Lenalidomide is an immunomodulator that has multiple effects on regulating the immune system, inhibiting tumor angiogenesis, and directly killing tumor cells. The combined use of the two is often used clinically to enhance the efficacy and prolong the survival of patients.

In terms of therapeutic effect, both bortezomib and lenalidomide alone can significantly improve the progression-free survival (PFS) and overall survival (OS) of patients with multiple myeloma, but combination therapy usually shows better efficacy. Multiple clinical studies have shown that the combination of bortezomib and lenalidomide can improve patients' treatment response rates, including higher complete response rates (CR) and partial response rates (PR), and effectively delay disease progression. The combination regimen is particularly suitable for patients with newly diagnosed multiple myeloma and patients with relapsed and refractory disease.

In terms of safety, although the combined use of bortezomib and lenalidomide improves the efficacy, it also brings a certain risk of side effects. For example, common side effects of bortezomib include peripheral neuropathy, thrombocytopenia, and gastrointestinal discomfort, while lenalidomide may cause hematologic toxicities such as neutropenia and venous thromboembolism. When using combination drugs, patients need to closely monitor these adverse reactions under the guidance of a doctor and adjust the dosage in a timely manner to ensure treatment safety.

In summary, the combination therapy of bortezomib and lenalidomide shows significant efficacy advantages in the treatment of multiple myeloma and can improve the patient's response rate and prolong survival. Although coadministration may increase the incidence of side effects, these risks can be effectively controlled with appropriate management and monitoring. In the future, with the accumulation of more clinical data and optimization of treatment options, the combination treatment of bortezomib and lenalidomide is expected to bring better treatment outcomes to patients with multiple myeloma.

Reference materials:https://www.drugs.com/donanemab.html